Literature DB >> 30143942

Targeted Therapies in the Treatment of Sarcomas.

Brianna Hoffner1, Anthony D Elias2, Victor M Villalobos1.   

Abstract

About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or experimental molecularly targeted agents in the clinic. In addition, immunotherapies may have a growing role in the treatment of sarcomas in the future.

Entities:  

Mesh：

Year:  2018        PMID： 30143942     DOI： 10.1007/s11523-018-0583-0

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


  60 in total

1.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

Review 2.  p53 as a target for the treatment of cancer.

Authors:  Michael J Duffy; Naoise C Synnott; Patricia M McGowan; John Crown; Darran O'Connor; William M Gallagher
Journal:  Cancer Treat Rev       Date:  2014-12       Impact factor: 12.111

Review 3.  Molecular pathways: CDK4 inhibitors for cancer therapy.

Authors:  Mark A Dickson
Journal:  Clin Cancer Res       Date:  2014-05-02       Impact factor: 12.531

4.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

Authors:  Ann W Gramza; Christopher L Corless; Michael C Heinrich
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

5.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

Authors:  Sandra P D'Angelo; Michelle R Mahoney; Brian A Van Tine; James Atkins; Mohammed M Milhem; Balkrishna N Jahagirdar; Cristina R Antonescu; Elise Horvath; William D Tap; Gary K Schwartz; Howard Streicher
Journal:  Lancet Oncol       Date:  2018-01-19       Impact factor: 41.316

6.  Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study.

Authors:  Lung Fung Tse; Kwok Chuen Wong; Shekhar Madhukar Kumta; Lin Huang; Tsun Cheung Chow; James Francis Griffith
Journal:  Bone       Date:  2007-09-06       Impact factor: 4.398

7.  Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.

Authors:  Victor Manuel Villalobos; Francis Hall; Antonio Jimeno; Lia Gore; Kenneth Kern; Rossano Cesari; Bo Huang; Jeffrey T Schowinsky; Patrick Judson Blatchford; Brianna Hoffner; Anthony Elias; Wells Messersmith
Journal:  Ann Surg Oncol       Date:  2017-09-08       Impact factor: 5.344

Review 8.  The role of radiation treatment in the contemporary management of bone tumors.

Authors:  Borislav Hristov; Ori Shokek; Deborah A Frassica
Journal:  J Natl Compr Canc Netw       Date:  2007-04       Impact factor: 11.908

9.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Authors:  Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel
Journal:  Lancet Oncol       Date:  2017-10-04       Impact factor: 41.316

10.  NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.

Authors:  Jin-Ping Lai; Avi Z Rosenberg; Markku M Miettinen; Chyi-Chia R Lee
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.